Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?

SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiovascular risk http://ow.ly/p6Is300ffoc

Detalles Bibliográficos
Autores principales: Andreas, Stefan, Janson, Christer, van den Berge, Maarten, Lahousse, Lies
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2016
Materias:
Clinical Signpost
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005175/
https://www.ncbi.nlm.nih.gov/pubmed/27730192
http://dx.doi.org/10.1183/23120541.00055-2016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005175/
https://www.ncbi.nlm.nih.gov/pubmed/27730192
http://dx.doi.org/10.1183/23120541.00055-2016

Ejemplares similares